LY 326325

Drug Profile

LY 326325

Latest Information Update: 22 Sep 2000

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antiepileptic drugs; Isoquinolines; Neuroprotectants; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 22 Sep 2000 No-Development-Reported for Neurological disorders (Prevention) in USA (PO)
  • 28 May 1998 New profile
  • 27 May 1998 Preclinical development for Neurological disorders (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top